Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) have been given an average rating of “Buy” by the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. Thirteen investment analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $81.78.
A number of research analysts recently issued reports on LEGN shares. Scotiabank boosted their price objective on Legend Biotech from $70.00 to $76.00 and gave the company a “sector outperform” rating in a research note on Monday, August 12th. TD Cowen dropped their price target on Legend Biotech from $71.00 to $67.00 and set a “buy” rating for the company in a research note on Monday, July 15th. BMO Capital Markets restated an “outperform” rating and issued a $90.00 price target on shares of Legend Biotech in a research note on Wednesday, July 3rd. Truist Financial began coverage on Legend Biotech in a research note on Monday, June 17th. They issued a “buy” rating and a $88.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $73.00 price target on shares of Legend Biotech in a research note on Monday, September 30th.
Read Our Latest Stock Analysis on LEGN
Institutional Trading of Legend Biotech
Legend Biotech Trading Up 2.7 %
Shares of NASDAQ:LEGN opened at $49.07 on Tuesday. The stock has a 50 day moving average of $53.12 and a 200 day moving average of $50.01. The company has a market cap of $8.94 billion, a PE ratio of -37.75 and a beta of 0.10. The company has a current ratio of 4.84, a quick ratio of 4.78 and a debt-to-equity ratio of 0.25. Legend Biotech has a 12-month low of $38.60 and a 12-month high of $70.78.
Legend Biotech (NASDAQ:LEGN – Get Free Report) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49. The company had revenue of $186.50 million during the quarter, compared to the consensus estimate of $125.25 million. Legend Biotech had a negative return on equity of 23.20% and a negative net margin of 62.50%. The firm’s revenue was up 154.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.27) EPS. As a group, equities research analysts expect that Legend Biotech will post -1.46 EPS for the current year.
Legend Biotech Company Profile
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Recommended Stories
- Five stocks we like better than Legend Biotech
- Where to Find Earnings Call Transcripts
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- What to Know About Investing in Penny Stocks
- MarketBeat Week in Review – 9/30 – 10/4
- Why Invest in High-Yield Dividend Stocks?
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.